Profound Medical Corp. (PROF)
Nasdaq: PROF · Surgical & Medical Instruments & Apparatus · Mississauga, ON · filing with the SEC since 2017
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
| Report filed | Mar 5, 2026 | Mar 7, 2025 | Mar 7, 2024 | Mar 7, 2023 |
| Revenue | 16,098 | 10,680 | 7,199 | · |
| Cost of revenue | 4,705 | 3,643 | 2,887 | · |
| Gross profit | 11,393 | 7,037 | 4,312 | · |
| Research and development | 20,596 | 16,965 | 14,424 | · |
| Selling, general and administrative | 32,051 | 23,134 | 18,539 | · |
| Total operating expenses | 52,647 | 40,099 | 32,963 | · |
| Operating income | -41,254 | -33,062 | -28,651 | · |
| Interest expense | 394 | 600 | · | · |
| Interest income (expense), net | 1,070 | 1,436 | 775 | · |
| Total non-operating income (expense) | -1,064 | 5,244 | 200 | · |
| Income before income taxes | -42,318 | -27,818 | -28,451 | · |
| Income tax expense | 252 | -2 | -128 | · |
| Net income including non-controlling interests | -42,570 | -27,816 | -28,323 | · |
| Net income | -42,570 | -27,816 | -28,323 | · |
| Net income to common shareholders | 42,570 | 27,816 | · | · |
| Earnings per share, basic | 1.41 | 1.12 | 1.34 | · |
| Earnings per share, diluted | 1.41 | 1.12 | 1.34 | · |
| Weighted average shares, basic | 30,232,966 | 24,765,503 | 21,182,558 | · |
| Weighted average shares, diluted | 30,232,966 | 24,765,503 | 21,182,558 | · |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:RevenuesCost of revenue what it cost to make or buy what it sold
us-gaap:CostOfRevenueGross profit revenue less the cost of what it sold
us-gaap:GrossProfitResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseSelling, general and administrative the cost of selling and of running the company
us-gaap:SellingGeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseDebtInterest income (expense), net interest earned less interest paid, outside the business
us-gaap:InterestIncomeExpenseNonoperatingNetTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income including non-controlling interests the whole group's profit, minority holders' share included
us-gaap:ProfitLossNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossNet income to common shareholders what is left for common shareholders
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasicEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding